Selection of aptamers against the Jagged-1 protein

Authors

  • Fábio Fernando Alves da Silva Nuclear and Energy Research Institute
  • Emerson Soares Bernardes

DOI:

https://doi.org/10.15392/2319-0612.2022.1933

Keywords:

Breast cancer, aptamer, Jagged-1

Abstract

The breast cancer is one of the biggest public health problems in the world, being the main female type of cancer that affects the population. The Jagged-1 protein plays an important role in the biology and development of cancer, influencing angiogenesis, growth of neoplastic cells, tumor stem cells, epithelial mesenchymal transition, metastatic processes and resistance to therapies in various types of cancer. In this project, our aim was to select an aptamer for JAG1 ligand using an aptamer library, that could be used as a radiopharmaceutical for PET / SPECT / CT diagnosis of tumors that express JAG1.  Our work showed that MDA-MB-231-JAG1 cells overexpress more mRNA and JAG1 protein than control cells (MDA-MB-231-Control). We also selected aptamers with high affinity for MDA-MB-231-JAG1 cells that could be a useful tool for the development of new radiopharmaceuticals for the diagnosis and treatment of tumors that overexpress JAG1.

 

 

Downloads

Download data is not yet available.

References

MS/INCA, “Estimativa de Câncer no Brasil, 2020,” 2020. https://www.inca.gov.br/numeros-de-cancer.

WHO, “Cancer,” World Health Organization, 2020.

C. Guarnaccia, A. Pintar, and S. Pongor, “Exon 6 of human Jagged-1 encodes an autonomously folding unit,” FEBS Lett., 2004. DOI: https://doi.org/10.1016/j.febslet.2004.08.022

Oda, T., Elkahloun, A.G., Pike, B.L., Okajima, K., Krantz, I.D., Genin, A., Piccoli, D.A., Meltzer, P.S., Spinner, N.B., Collins, F.S., Chandrasekharappa, S.C.,Oda, T., Elkahloun, A.G., Pike, B.L., Okajima, K., Krantz, I.D., Genin, A., Piccoli, D.A., Melt, “Mutations in the human Jagged1 gene are responsible for Alagille syndrome,” Nat. Genet., vol. 16, pp. 235–242, 1997. DOI: https://doi.org/10.1038/ng0797-235

M. Gijs, A. Aerts, N. Impens, S. Baatout, and A. Luxen, “Aptamers as radiopharmaceuticals for nuclear imaging and therapy,” Nucl. Med. Biol., vol. 43, no. 4, pp. 253–271, 2016, doi: 10.1016/j.nucmedbio.2015.09.005. DOI: https://doi.org/10.1016/j.nucmedbio.2015.09.005

P. J. Bates, E. M. Reyes-reyes, M. T. Malik, E. M. Murphy, M. G. O. Toole, and J. O. Trent, “G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent : Uses and mechanisms,” Biochim. Biophys. Acta, vol. 1861, no. 5, pp. 1414–1428, 2017, doi: 10.1016/j.bbagen.2016.12.015. DOI: https://doi.org/10.1016/j.bbagen.2016.12.015

C. E. B. De Almeida, L. Nascimento, H. F. Rocha, J. B. Cabral-neto, and S. Missailidis, “Aptamer delivery of siRNA , radiopharmaceutics and chemotherapy agents in cancer,” Int. J. Pharm., vol. 525, no. 2, pp. 334–342, 2017, doi: 10.1016/j.ijpharm.2017.03.086. DOI: https://doi.org/10.1016/j.ijpharm.2017.03.086

F. Maleki, F. Rezazadeh, and K. Varmira, “MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy,” 2021, doi: 10.1021/acs.molpharmaceut.0c01249. DOI: https://doi.org/10.1021/acs.molpharmaceut.0c01249

Downloads

Published

2022-12-04

How to Cite

Alves da Silva, F. F., & Bernardes , E. S. . (2022). Selection of aptamers against the Jagged-1 protein. Brazilian Journal of Radiation Sciences, 10(3B (Suppl.). https://doi.org/10.15392/2319-0612.2022.1933

Issue

Section

INAC 2021_XV ENAN